Intec Pharma’s Accordion Pill flunks late-stage Parkinson’s study

Thinly traded nano cap Intec Pharma Ltd. (NASDAQ:NTEC) craters 78% premarket in reaction to its announcement that its Accordion Pill-Carbidopa/Levodopa failed to demonstrate superiority over Merck’s (NYSE:MRK) Sinemet (Carbidopa-Levodopa) in terms of reduction in daily OFF time in a Phase 3 clinical trial, ACCORDANCE, in Parkinson’s disease patients.

Management will host a conference call this morning at 8:30 am ET to discuss the data.

https://seekingalpha.com/news/3479569-intec-pharmas-accordion-pill-flunks-late-stage-parkinsons-study-shares-78-percent-premarket